Pipeline-Prospector-Insert
X

Find drug development pipeline and deal Updates information

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Company Locations

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): RXC007

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 09, 2020

            Details:

            Preclinical data with compounds from Redx’s ROCK2 programme have demonstrated robust anti-fibrotic effects in a range of industry-standard in vivo models.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OSP-101

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Altavant Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition January 08, 2020

            Details:

            This acquisition expands Altavant’s pipeline to include OSP-101, a novel inhaled interleukin-1 receptor antagonist (IL-1Ra) with orphan drug designation from the U.S. Food and Drug Administration.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AT-100

            Therapeutic Area: Pulmonary/Respiratory Diseases

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $15.5 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing January 08, 2020

            Details:

            This funding will enable clinical development of AT-100 (rhSP-D), while also supporting preclinical research in influenza, respiratory syncytial virus (RSV) and cystic fibrosis.